ClinicalTrials.gg
TerminatedNCT01510847OTESTUpdated Jan 6, 2016

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

A Phase 4 interventional study of Andriol Testocaps in Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events., sponsored by Singapore Clinical Research Institute. Terminated at 12 sites in Singapore. Open to male participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-01-06.

Sponsored by Singapore Clinical Research Institute · Phase 4, Interventional, and Supportive care

Why this study was terminated
Unable to reach the target recruitment within timeline
Phase
Phase 4
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
45 Years to 75 Years
Sex
Male
01

Study summary

The study hypothesis is that treatment with oral Testosterone according to the study regimen will improve glycemic control in T2DM Chinese males in Singapore as indicated by a reduction in HbA1c levels at study day 90.

Read the detailed description

This is a single arm open label clinical study in Chinese men of 45 to 75 years of age with Type 2 Diabetes. Subjects will be recruited from participating family medicine clinics with the FMRN and followed for 90-days. All subjects will continue on pre-study treatment regimens and medications as clinically indicated throughout the 90-day study period. Missed doses of study drug can be made up within the same day. With the exceptions of study drug and diabetic medications, changes in other medications will be permitted. The primary aim is to assess the effects of oral Testosterone on change in HbA1c levels in the Chinese males with a diagnosis of T2DM over a 90-day study period.

Subjects enrolled in the study will take two 40mg capsules of oral testosterone in the morning and two 40mg capsules in the evening with meals on both occasions on each day. This daily dosage is consistent with the recommended dosage for subjects being treated for hypogonadism.

Primary objective:

  • The primary aim is to assess the effect of oral Testosterone on percent change in HbA1c in T2DM Chinese males in Singapore over a 90-day study period.

Secondary objectives:

  • The secondary aim is to assess the effects of site, eugonadism and hypogonadism, and the prognostic relevance of baseline levels of HbA1c, total testosterone, PSA, IPSS, haemoglobin and haematocrit on 90-day change and percent change from baseline in HbA1c under the study Testosterone regimen.

All subjects must satisfy ALL of the following criteria at study entry:

  • Subject is a Chinese male
  • Subject is 45 to 75 years old
  • Subject has T2DM with no change in type/dose of diabetic medication in the last 3 months
  • Subject's Haemoglobin level is between 13.5 - 18g/dl
  • Subject's Haematocrit level is 40 - 54%
  • Subject's Albumin level is between 3.5 - 5.0 g/dL
  • Subject's Alanine transaminase (ALT) level is up to 36 U/L
  • Subject's Aspartate transaminase (AST) level is \< 41 U/L
  • Subject's Alkaline phosphatase (ALP) level is \< 130 U/L
  • Subject's Creatinine(up to 60 years) level is between 0.57 - 1.36 mg/dL
  • Subject's Creatinine(> 60 years) level is between 0.68 - 1.48 mg/dL
  • Subject's Sodium(13 to 65 years) level is between 136 - 145 mmol/L
  • Subject's Sodium(> 65 years) level is between 132 - 146 mmol/L
  • Subject's Potassium (up to 59 years) level is between 3.3 - 5.1 mmol/L
  • Subject's Potassium (> 59 years) level is between 3.7 - 5.4 mmol/L
  • Subject's PSA (Prostate Specific Antigen) level is ≤ 4ug/L
  • Subject's Total Testosterone level is between 8.4 - 28.7 nmol/L
  • Satisfactory haematological or biochemical functions tests only - these tests should be carried out during the screening period prior to enrolment. Patient with mild laboratory abnormalities can be included at the discretion by the site/co-investigator, and after approval by Co-ordinating Principal Investigator
  • Written Informed Consent is obtained
  • Subject is willing to comply with study procedures and is able to return to the clinic for scheduled visits

All subjects must NOT have any of the following criteria at study entry:

  • Subject's HbA1C level is > 9%.
  • Subject is on insulin therapy
  • Subject has history of recurrent hypoglycaemia
  • Subject has history of malignancy (except skin cancer) during last 5 years
  • Subject has received treatment for endocrinopathy within the last 3 months (except diabetes)
  • Subject has history of adverse drug reaction to testosterone
  • Subject has received testosterone replacement within the last 3 months
  • Subject is currently receiving warfarin, steroids, cyclosporine or thyroxine
  • Subject has history of Myocardial Infarction
  • Subject has history of Angina
  • Subject has heart failure which causes at least slight limitation of physical activity. Subject is comfortable at rest, but ordinary physical activity results in fatigue, palpitation or dyspnea
  • Subject has history of Deep Vein Thrombosis or Stroke
  • Subject has history of prostate cancer
  • Subject has history of chronic kidney disease , Stage 3 or worse
  • Subject has life expectancy of less than 1 year
  • Subject has enlarged prostate per digital rectal examination
  • Subject's International Prostate Symptom Score (IPSS) is greater than 20

Blood samples will be drawn during the study period:

  • 16 types of blood samples at Baseline, Month 1 and Month 3 Visits.
  • HbA1c, Haemoglobin, Haematocrit, Albumin, ALT, AST, ALP,Creatinine,PSA, Total Testosterone, Total Cholesterol,HDL, LDL, Triglycerides, Sodium,Potassium
02

Conditions studied

  • Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.
03

In context

Lead sponsor

Singapore Clinical Research Institute is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a Chinese male
  • Subject is 45 to 75 years old
  • Subject has T2DM with no change in type/dose of diabetic medication in the last 3 months
  • Subject 's level is between 13.5 - 18g/dl
  • Subject's Haematocrit level is 40 - 54%
  • Subject's Albumin level is between 3.5 - 5.0 g/dL
  • Subject's (ALT) level is up to 36 U/L
  • Subject's Aspartate transaminase (AST) level is \< 41 U/L
  • Subject's Alkaline phosphatase (ALP) level is \< 130 U/L
  • Subject's Creatinine (up to 60 years) level is between 0.57 - 1.36 mg/dL
  • Subject's Creatinine (> 60 years) level is between 0.68 - 1.48 mg/dL
  • Subject's Sodium (13 to 65 years) level is between 136 - 145 mmol/L
  • Subject's Sodium ( > 65 years) level is between 132 - 146 mmol/L
  • Subject's Potassium ( up to 59 years) level is between 3.3 - 5.1 mmol/L
  • Subject's Potassium ( > 59 years) level is between 3.7 - 5.4 mmol/L
  • Subject's PSA (Prostate Specific Antigen) level is ≤ 4ug/L
  • Subject's Total Testosterone level is between 8.4 - 28.7 nmol/L
  • Satisfactory haematological or biochemical functions tests only - these tests should be carried out during the screening period prior to enrolment. Patient with mild laboratory abnormalities can be included at the discretion by the site/co-investigator, and after approval by Co-ordinating Principal Investigator
  • Written is obtained
  • Subject is willing to comply with study procedures and is able to return to the clinic for scheduled visits

Exclusion criteria

Exclusion Criteria:

  • Subject's level is > 9%.
  • Subject is on insulin therapy
  • Subject has history of recurrent hypoglycaemia
  • Subject has history of (except skin cancer) during last 5 years
  • Subject has received treatment for endocrinopathy within the last 3 months (except diabetes)
  • Subject has history of adverse drug reaction to testosterone
  • Subject has received testosterone replacement within the last 3 months
  • Subject is currently receiving warfarin, , cyclosporine or thyroxine
  • Subject has history of Myocardial Infarction
  • Subject has history of Angina
  • Subject has heart failure which causes at least slight limitation of physical activity. Subject is comfortable at rest, but ordinary physical activity results in fatigue, palpitation or dyspnea
  • Subject has history of Deep Vein Thrombosis or Stroke
  • Subject has history of prostate cancer
  • Subject has history of chronic kidney disease , Stage 3 or worse
  • Subject has of less than 1 year
  • Subject has enlarged prostate per digital rectal examination
  • Subject's International Prostate Symptom Score (IPSS) is greater than 20
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Other
    Oral Testosterone Therapy

    90 day oral testosterone therapy

    Drug: Andriol Testocaps

Interventions

  • DrugAndriol Testocaps

    Oral, 40mg, Twice a day, 30days

06

What researchers measure

Primary outcomes

  1. The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST

    The primary aim is to assess the effect of oral Testosterone Supplementation on percent change in HbA1c in Type 2 Diabetes Mellitus Chinese males in Singapore over a 90-day study period.

    Time frame: 90 Day Study Period

Secondary outcomes

  1. The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST

    The secondary aim is to assess the effects of site, eugonadism and hypogonadism, and the prognostic relevance of baseline levels of HbA1c, total testosterone, PSA, IPSS, haemoglobin and haematocrit on 90-day change and percent change from baseline in HbA1c under the study Testosterone Supplementation regimen.

    Time frame: 90 day study period

07

Study locations

12 sites
  • Camry Medical Centre
    Singapore, 310095, Singapore
  • Frontier Medical Associates (Ubi) Pte Ltd
    Singapore, 400305, Singapore
  • Everhealth Medical Centre
    Singapore, 530540, Singapore
  • Frontier Medical Associates (Buangkok Cresent) Pte Ltd
    Singapore, 530982, Singapore
  • Frontier Medical Associates (AMK) Pte Ltd
    Singapore, 560163, Singapore
  • EJ Tan Clinic & Surgery
    Singapore, 600104, Singapore
  • Everhealth Family Clinic & Surgery
    Singapore, 640762, Singapore
  • Bukit Batok Medical Clinic
    Singapore, 650207, Singapore
  • Princeton Family Clinic Pte Ltd
    Singapore, 670445, Singapore
  • The Edinburgh Clinic
    Singapore, 680306, Singapore
  • Frontier Medical Associates (Woodlands) Pte Ltd
    Singapore, 732899, Singapore
  • Frontier Medical Associates (Yishun) Pte Ltd
    Singapore, 760654, Singapore
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2012
First posted
Jan 18, 2012
Start
Oct 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Jan 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01510847
Lead sponsor
Singapore Clinical Research Institute
Collaborators
Singapore General Hospital, Duke-NUS Graduate Medical School
Responsible party
Sponsor
First posted
Jan 18, 2012
Start date
Oct 2011
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Jan 6, 2016

Study contacts

Sam Lim, MBBS
principal investigator · Singapore Clinical Research Institute Pte Lte

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion